Stay updated with breaking news from Lowest Dose. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
- In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose-Dependent Splicing Correction, Muscle Delivery and DMPK Knockdown - - All Evaluable Patients in the 3.4 mg/kg Cohort Treated with DYNE-101...
- In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose-Dependent Splicing Correction, Muscle Delivery and DMPK Knockdown -
100% Tumor Shrinkage at 2-months in advanced metastatic colorectal cancer was demonstrated by IMX-110 + BeiGene / Novartis anti-PD-1 Antibody Tislelizumab combination in the first, lowest dose cohort ... | May 3, 2023
It’s an increasingly common trend: U.S. adults who are taking a stimulant medication, together with other drugs that target the central nervous system, such as antidepressants, opioids, and anti-anxiety medications.